Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon α for metastatic melanoma: A multicentre phase II study

British Journal of Cancer

Volumn 76, Issue 2, 1997, Pages 266-269

  Punt, C J A ^a   Van Herpen, C M L ^a   Jansen, R L H ^b   Vreugdenhil, G ^c   Muller, E W ^d   De Mulder, P H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST JOSEPH HOSPITAL   (Netherlands)

^d SLINGELAND HOSPITAL   (Netherlands)

Author keywords

Chemoimmunotherapy; Chemotherapy; Interferon ; Metastatic melanoma

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; DACARBAZINE; LOMUSTINE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FATIGUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALAISE; MELANOMA; METASTASIS; MULTICENTER STUDY; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0030959126     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.374     Document Type: Article

References (30)

1. Atkins MB, Oboyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K. Mier JW, Sparano JA, Fisher RI, Eckardt JR, Pereira C and Aronson FR (1994) Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12: 1553-1560
2. Bajetta E, Dileo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, Giannotti B, Queirolo P, Tribbia G, Bernengo MG, Menichetti ET, Palmeri S, Russo A, Cristofolini M, Erbazzi A, Fowst C, Criscuolo D, Bufalino R, Zilemho N and Cascinelli N (1994) Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2A in the treatment of advaneed melanoma. J Clin Oncol 12: 806-811
3. Balch CM, Soong SJ, Shaw HM, Urist MM and McCarthy WH (1992) An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In Cutaneous Melanoma, Balch CM, Houghton AN, Milton GW, Sober AJ and Soong SJ (eds), pp. 165-187. JB Lippincott: Philadelphia
4. Buzaid AC and Legha SS (1994) Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 21: 23-28
5. Cantell K, Hirvonen S and Koistinen V (1981) Partial purification of human leucocyte interferon on a large scale. Methods Enzymol 78: 499-505
6. Del Prete SA, Maurer LH, O'Donnel J, Forcier RJ and Lemarbre P (1984) Combination chemotherapy with cisplatin. carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403-1405
7. Falkson CI, Falkson G and Falkson HC (1991) Improved results with the addition of Interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9: 1403-1408
8. Falkson CI, Ibrahim J, Kirkwood J and Blum R (1996) A randomized phase III trial of dacarbazine (DTIC) versus DTIC + interferon alfa-2b (IFN) versus DTIC + tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: an ECOG trial (abstract). Proc Am Soc Clin Oncol 15: 435
9. Fiedler W, Jasmin C, DE Mulder PHM, Pyrhönen S, Palmer PA, Franks CR, Oskam and Hossfeld DK (1992) A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur J Cancer 28: 443-146
10. Hernberg M, Muhonen T, Turunen JP, Hahka-Kemppinen M and Pyrhönen S (1996) The CD4 + /CD8 + ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol 14: 1690-1696
11. Houghton AN, Legha S and Bajorin DF (1992) Chemotherapy for metastatic melanoma. In Cutaneous Melanoma, Balch CM (ed.), pp. 499-508. JB Lippincott: Philadelphia
12. Karakousis CP, Emrich LJ and Rao U (1986) Groin dissection in malignant melanoma. Am J Surg 152: 491-197
13. Keilholz U, Goey SH, Punt CJA, Proebstle T, Salzmann R, Schadendorf D, Lienard D, Scheibenbogen C and Eggermont AAM (1996) A randomized trial of IFNα/IL-2 with or without CDDP in advanced melanoma: an EORTC Melanoma Cooperative Group trial (abstract). Proc Am Soc Clin Oncol 15: 436
14. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks R, Auclerc G, Soubrane C. Banzet P and Weil M (1993) Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11: 2173-2180
15. Kirkwood JM (1995) Melanoma. In Biologic Therapy of Cancer: Principles and Practice, DeVita VT, Jr. Hellman S and Rosenberg SA (eds). pp. 388-411 JB Lippincott: Philadelphia
16. Kruit WH, Punt CJA, Goey SH, Demulder PH, Vanhoogenhuyze DC, Henzenlogmans SC and Stoler G (1994) Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon - An unexpectedly frequent complication. Cancer 74: 2850-2856
17. Kruit WHJ. Punt CJA, Goey SH, DE Mulder PHM, Gratama JW, Eggermont AMM, Bolhuis RLH and Stoter G (1996) Dose-efficacy study of two schedules of high-dose bolus administration of interleukin-2 and alpha-interferon in patients with metastatic melanoma. Br J Cancer 74: 951-955
18. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S and Benjamin R (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64: 2024-2029
19. McClay EF, Mastrangelo MJ, Berd D and Bellet RE (1992) Effective combination chemohormonal therapy for malignant melanoma: experience with three consecutive trials, Int J Cancer 50: 553-556
20. Marincola FM, White DE, Wise AP and Rosenberg SA (1995) Combination therapy with interferon ALFA-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 13: 11 10-1122
21. Marincola FM and Rosenberg SA (1995) Biologic therapy with interleukin-2: clinical applications. Melanoma. In Biologic Therapy of Cancer, DeVita VT, jr. Hellman S and Rosenberg SA (eds), pp. 250-262. JB Lippincott: Philadelphia
22. Mulder NH, Vandergraaf WTA, Willemse PHB, Koops HS, Devries EGE and Sleijfer DT (1994) Dacarbazine (DTIC)-hased chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. Br J Cancer 70: 681-683
23. Prudente Foundation Melanoma Study Group (1989) Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer 63: 1676-1680
24. Pyrhönen S, Hahka-Kemppinen M and Muhonen T (1992) A promising interferon plus tour-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10: 1919-1926
25. Richards JM, Mehta N, Ramming K and Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338-1343
26. Seigler HF, Lucas VS, Pickelt NJ and Huang AT (1980) DTIC, CCNU, bleomyein and vincristine (BOLD) in metastatic melanoma. Cancer 46: 2346-2348
27. Singletary SE and Balch CM (1992) Recurrent regional metastases and their management. In Cutaneous Melanoma, Balch CM, Houghton AN, Milton GW, Sober AJ and Soong SJ (eds), pp. 427-435. JB Lippincott: Philadelphia
28. Stoter G, Aamdal S, Rodenhuis S, Cleton FJ, Iacobelli S, Franks CR, Oskam R and Shiloni E (1991) Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter study. J Clin Oncol 9: 1687-1691
29. Thompson DB, Adena M, McLeod GRC, Hersey P, ,Gill PG, Coates AS, Olver IN, Kefford RF, Lowenthal RM, Beadle GF, Walpole ET, Boland K and Kingston D (1993) Interferon-α2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 3: 133-138
30. York M and Foltz AT (1988) Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 61: 2183-2186